Mobile Telemedicine for Diabetes Care by Martínez Sarriegui, Iñaki et al.
MOBILE TELEMEDICINE FOR DIABETES CARE 
Iñaki Martínez-Sarriegui1'3, Gema García Sáez1'3, Ma. Elena Hernando1'3, 
Mercedes Rigla2'3, Eulalia Brugués2'3, Alberto de Leiva2'3, Enrique J. Gómez1'3 
1
 Bioengineering and Téleme dicine Group 
Technical University of Madrid 
Ciudad Universitaria, 28040 Madrid, Spain 
2
 Endocrinology Department 
Hospital Sant Pau 
Mas de Casanovas 90, 08025 Barcelona, Spain 
3CIBER-BBN: Bioengineering, Biomaterials and Nanomedicine Networking 
Research Centre 
Instituto de Salud Carlos III, 
Sinesio Delgado 6, 28029 Madrid, Spain 
E-mail: imartinez@gbt. tfo. upm. es 
Diabetes Mellitus is nowadays one of the most frequent non-contagious 
diseases in the world and remains a major health problem for the 
national health care programs. It is well proved that Telemedicine helps 
diabetic patients controlling their glucose levéis, facilitating their day-
to-day therapy management and the communication with health care 
personnel. The rapid growth and development of information 
technologies in the áreas of mobile computing and mobile Internet is 
shaping a new technological scenario of telemedicine and shared care 
systems. In this chapter we will show one approach to Mobile 
Telemedicine for Diabetes Care. 
1. Introduction 
According the International Diabetes Federation1 5.1% of the world 
population suffers from diabetes and the forecast for 2025 is that it will 
increase to the 6.3%. In Western societies the numbers rise to the 7.8% 
nowadays and 9.5% by 2025. The situation of diabetes makes heavier 
due to the number of people with alteration of glucose tolerance that 
affects to the 8.2% of the world population and by 2025 it will affect to 
the 9%. Another alarming fact is that for each case of diagnosed diabetes 
there is another that is not diagnosed. 
Diabetes remains a major health problem being responsible of up to 8% 
of national health care expenditure2 Diabetes Mellitus is a chronic 
disease characterised by a sustained elevated blood glucose level, caused 
by a reduction in the action of insulin secretion where related metabolic 
disturbances genérate severe, acute and long-term complications that are 
responsible for premature death and disability3. The World Health 
Organization projects that diabetes deaths will increase by more than 
50% in the next 10 years without urgent action4. Most notably, diabetes 
deaths are projected to increase by over 80% in upper-middle income 
countries between 2006 and 2015. 
Due to its multifactorial and systemic character, diabetes mellitus has 
been considered a paradigm of chronic disorders which has led to an 
extensive application of information technologies in diabetes care5. 
Nowadays telemedicine provides an integrated approach to information 
technology tools, which enhances co-operation between users, 
information and knowledge sharing. 
Over the last three decades, diabetes has been a mayor focus for 
biomedical engineering efforts to improve the diagnosis, monitoring and 
treatment of diabetic people. Earlier experiences aimed to facilítate the 
remote monitoring of patients from home by the transmission of 
computerised blood glucose profiles to the hospital6'7'8. Most of 
interactive telemedicine services were delivered using a distributed 
approach integrating "Patient Units" (PU), implemented on a personal 
computer or a palmtop and used by patients during their daily living; and 
"Medical Workstations" (MW), used by physicians and nurses at the 
hospital9101112. Technology evolution has enabled the development of 
advanced systems based on more powerful, portable and easy to use 
termináis and applications, such as hand-held electronic diaries with 
touch-screen13, video telephones14, or web-based prototype systems915. 
The rapid growth and development of information technologies during 
recent years in the áreas of mobile computing, computer-telephony 
integration (CTI) and mobile Internet is changing the way people access 
to common services. Today people can buy cinema tickets, consult the 
trafile situation, pay their bilis and many other actions with their mobile 
telephone or PDA. And a growing sector of citizens demands more 
services available in a mobile way. 
As more and more people use mobile handsets, a revolution is taking 
place in computing and telecommunications. Two extraordinary 
industries -the Internet and mobile Communications- are converging. But 
this is just the beginning. As the third industry -consumer electronics-
and the fourth -media and entertainment- join in changes in consumer 
markets are inevitable, as evidenced by the explosive growth of mobile 
media, games and entertainment16. 
Telemedicine and shared care systems should not obviate the technology 
and market evolution. Today the seamless integration of available mobile 
and wireless technologies allows building a new scenario for 
telemedicine and shared care in diabetes in which the traditional concepts 
of PU and MU are blurred, suffering a profound transformation evolving 
to a new multi-access, mobile, universal and ubiquitous workspace 
concept for diabetes care17. 
In this chapter we present the telemedicine services requisites and the 
technical requirements of mobile telemedicine systems for diabetes care. 
These considerations were taken into account to build a multi-access 
mobile telemedicine workspace, implemented over the sustenance of a 
multi-agent architecture. This workspace provides universal access to a 
wide range of services both for patients and professionals. The chapter 
finishes drawing some conclusions about the current telemedicine and 
shared care experiences and the possibilities of mobile technologies in 
diabetes care in the future. 
2. The Diabetes Care challenge 
2.1 The medicalproblem 
Diabetes Mellitus is a group of metabolic diseases characterised by a 
sustained elevated blood glucose level (hyperglycemia), caused by 
defeets in insulin secretion, insulin action or both. Insulin facilítates entry 
of glucose into muscle, adipose and several other tissues and stimulates 
the liver to store glucose in the form of glycogen. The chronic 
hyperglycemia generates severe, acute and long-term complications that 
are responsible for premature death and disability3. The cause of diabetes 
continúes to be a mystery, although both genetics and environmental 
factors such as obesity and lack of exercise appearto play roles18. 
The vast majority of cases of diabetes fall into three broad categories: 
Type 1, Type 2 and gestational diabetes19. Type 1 diabetes comprises 
10% of all cases with diabetes. The cause is an absolute deficiency of 
insulin secretion due to beta cells destruction, and the glucose cannot be 
metabolized. People with type 1 diabetes need insulin administration to 
use glucose from meáis. By taking a good control of blood glucose 
levéis, type 1 diabetic patients can expect to have an almost normal life 
span as the benefits of intensive therapy management have been well 
established and include reduced long-term complications20. 
Type 2 is the most prevalent form of diabetes, comprising 90% of 
diabetes cases. It results from a combination of resistance to insulin 
action and an inadequate compensatory insulin secretor response. People 
with type 2 need diabetes oral medication or insulin injections to control 
their blood glucose levéis. The inability of a large proportion of the 
population in the more affluent western societies to cope with the excess 
caloric supply together with a lack of physical exercise results in a 
greater prevalence of Type 2 diabetes. 
Gestational diabetes may give rise to several adverse outcomes, 
including congenital malformations, increased birth weight and an 
elevated risk of prenatal mortality and affects about 4% of all pregnant 
women. Strict metabolic control may reduce these risks to the level of 
those of non-diabetic expectant mothers. 
2.2. Diabetes Treatment 
Effective control of patients' blood glucose level minimizes the 
progression of the disease and reduces the risk of long-term neurological, 
renal and cardiovascular complications. The treatment of diabetic 
patients attempts to achieve normoglycemia by maintaining a careful 
balance between diet, physical exercise and insulin therapy. 
Patients monitor their own blood glucose levéis (self-monitoring) during 
the daily life to predict and avoid hypoglycemia (low blood sugar level) 
and hyperglycemia (high blood glucose level) and to take decisions 
regarding the adjustment of changes of insulin doses, meáis and physical 
activity. 
Insulin therapy aims to mimic the physiological insulin patterns 
delivered by the páncreas in non-diabetic people with the injection of 
short-acting insulin given under the skin (subcutaneously) just before the 
meal and long-acting insulin given in the morning and evening to 
simúlate the basal supply. 
Insulin cannot be orally taken as it would be broken down during 
digestión. Therefore, insulin must be injected and its efficiency depends 
on when glucose from the taken food starts to enter your blood18 and in 
what place of the body is injected. 
Scientific prospective studies have provided evidence on the use of 
intensive insulin therapy, based on múltiple insulin injections or 
continuous insulin delivering, as the most appropriate method to 
equilíbrate patient's blood glucose and to delay the onset and slow the 
progression of complications later in life. 
To obtain the best care outcomes, diabetic people should receive medical 
care from a physician-coordinated team21. Such teams may include 
physicians, nurses, dieticians, pharmacists and mental health 
professionals with expertise and interest in diabetes. They assess the 
patients' glycemic control on the basis of patient reported monitoring 
blood glucose data as well as by the glycated hemoglobin (HbAlc) test, 
which provides an indication of the average blood glucose level over the 
previous 2 to 3 months. This collaborative and integrated shared care 
approach requires that individuáis with diabetes assume an active role in 
their care requiring in many cases a better patient empowerment and 
education. 
However the fulfilment of the current guidelines in diabetes 
management22 implies a significant increase in the amount of patient data 
to be monitored, increasing physicians and nurses' workload and raising 
immediate health care costs. 
2.3. Telemedicine and Shared Care Services in Diabetes Management 
A telemedicine system for chronic care has to help physicians' decisión 
making. In the case of diabetes mellitus the responsibility of data 
collection is shared between patients, who record data during daily life 
(self-monitoring data) and the healthcare personnel, who capture data 
during hospital visits (hospital patient record) This suppose a huge 
quantity of data and increases physicians' workload analyzing them in 
order to take therapeutic decisions. The telemedicine system must 
provide enough information to enable assessment of the patient's 
condition and must present the relevant patient clinical data to define a 
therapeutic change. It should analyse patient's data, filtering the 
information, and genérate automatic intelligent alarms to focus doctors' 
attention on those points where non-desired deviations in the metabolic 
control are found. 
A telemedicine system for diabetic people has to provide Telemonitoring 
of the patients' monitoring data in order to allow physicians knowing the 
state of the patient. It should also allow Teleconsultation between 
patients and doctors through an asynchronous message exchange. 
Another service that it must supply is the Supervised Care, providing 
patients with a "supervised autonomy". Patients carry out day-to-day 
therapy changes and send this information to the physician who reviews 
the data and validates patients' decisions or proposes further adjustments 
of the treatment. 
To obtain the best care outcomes, diabetic people should receive medical 
care firom a physician-coordinated team. The information technologies 
provide with helpful tools for this coordination. One example is the 
application of Computer Supported Collaborative Work (CSCW) current 
theories and tools to créate new information technologies and 
telecommunication workspaces to bear diabetes shared care23. 
The services to be provided by a shared care workspace for diabetes 
management are: Multi-channel messaging services, to allow users to 
send and receive messages in any format despite of the original 
message's format; Shared information dissemination and request, to 
send data automatically to users interested on them using both pulí and 
push methods; Group and activity awareness: to intégrate an event and 
activities notification service -the aim of this service is to aware every 
user of the most relevant events occurring at the lowest cost-; Shared 
agenda (scheduling meeting/visits), this facility let users to share an 
agenda complementing the above services. 
2.4. Ambulatory artificial páncreas 
The combination of insulin pumps and continuous glucose monitoring 
systems seems to be the best current solution to achieve a good metabolic 
control for insulin-dependent diabetic people. Continuous glucose 
monitoring can detect glycemia patterns that cannot be discovered only 
by means of few diary measurements24. The possibility to obtain a 
complete blood glucose profile allows monitoring the suitability of an 
intensive therapy and can be used to fine-tune the therapy. The oíd 
concept of the "artificial páncreas" is starting to be a reality supported by 
the availability of these technologies and the integration of control 
systems able to cióse the loop modifying the pump parameters25. 
A closed-loop device capable of maintaining normoglycemia over 
extended periods of time could dramatically improve the quality of 
metabolic control of insulin-dependent diabetic patients26. An artificial 
páncreas contains three primary components: 1) An insulin pump; 2) A 
continuous glucose sensor; and 3) A closed-loop mathematical algorithm 
to regúlate the pump given a sensor measurement. 
Over the last decades, the development of an artificial páncreas has been 
a huge challenge on the application of biomedical technologies to 
diabetes therapy. The evolution of continuous glucose monitoring and 
insulin pumps technologies is creating a very promising situation in the 
next future. However, the current reliability constraints of continuous 
glucose sensor, the non-linearity of the glucoregulatory system and the 
inherent complexity of the design of a glucose controller for a SC-SC 
(SC, subcutaneous) setup are still some of the problems to be faced 
before obtaining a portable artificial páncreas. 
3. Technical Requirements of Mobile Telemedicine Systems for 
Diabetes Care 
We have seen some of the requirements of Telemedicine and Shared 
Care Systems for diabetes care. These requirements are general but for 
mobile systems there are some considerations and other requirements 
that we should consider. 
The applications that are supposed to rule on a mobile device, PDA or 
mobile telephone, have to take into account the following 
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considerations ' ' : 
• Concise contení: Only show relevant information using 
understandable abbreviations. 
• Current process recuperation: The user's task could be 
interrupted by a phone cali or a loss of coverage. The application 
must recover the process after the interruption. 
• Writing options: Include all predictable texts in order to avoid 
user inserting it because of the text input limitations of mobile 
devices. 
• Navigation: It is recommended that the application has a lot of 
categories with low depth. The information introduced should be 
stored in order to guarantee backward navigation. 
• Reduce the number of keystrokes: Especially in mobile 
telephones where the text input is made with several keystrokes 
for each letter. 
• Velocity: When the application makes use of Internet it has to be 
considered that the user pays for time or transmitted bytes so the 
connection should be fast enough. 
• Device limitations: Mobile devices have limitations of battery, 
velocity of process, storage capacity and graphic. These 
limitations must be considered at the design phase. 
• Easy-to-use interface: The system should provide simple 
interfaces. 
• Media adaptability: The system should provide support for 
different data: images, video and text. 
• Modular design: The system should have a modular design so 
that it allows for the development of a roadmap for growth that 
can accommodate future generations of functionality 
The implementation of an Ambulatory Artificial Páncreas requires 
additionally features: 
• Always-on technology: The closed loop algorithms have to run 
24 hours a day, reading continuous glucose devices and 
operating insulin pumps in real time. Robust devices and long 
duration batteries are crucial for this critical task. 
• Services for remote supervisión. PDA's applications usually 
work as client processes unable to provide information to 
external agents. The artificial páncreas application requires to 
include server functionalities (e.g. RPC or distributed CORBA 
objects) to allow remote supervisión and even remote operation 
of medical devices. 
Moreover, any mobile telemedicine application must fulfill some other 
requirements: 
• Security: Health care data are protected by official privacy laws 
and data protection. Therefore mobile telemedicine application 
must be very careful with the security at all levéis: 
communication, storage... 
• Communication with medical devices: This communication can 
be wireless (i.e.Bluetooth, IrDA, WiFi) or by cable. In any case 
the security and integrity of the data transferred from/to the 
medical device should be guaranteed. 
• Controllability: The system should support remote control 
functions. The healthcare provider should be empowered with 
the ability to control the media content according to medical 
specialties or his/her personal preference. For example, the 
health provider is allowed to control ECG sample rate, video 
frame rate, and image quality, etc. 
4. Building the Mobile Telemedicine System 
Actually there are different Mobile Telemedicine applications for 
Diabetes Care. Some mobile companies are commercializing mobile 
solutions that allow patients download data to a mobile telephone from a 
glucometer using a cable30, via Bluetooth31, IrDA32. Besides, some other 
systems download data from the glucometer to a prívate network via a 
long range wireless connection33. 
Patients and doctors can access to the data in the network using a web 
based application or a mobile telephone application. Some applications 
provide more facilities like manual data recollection or graphic 
visualization of previous data in addition to data analysis and alarm 
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generation . 
There are some non-commercial experiences that allow glucometer data 
downloading35'36. Another mobile application for diabetes care uses 
mobile telephone to develop text messages with specific behavioral 
health strategies to young diabetes patients37. 
In this section we are going to talk about the DIABTel Telemedicine 
System for Type 1 diabetic patients developed by the authors. DIABTel 
is a multi-access mobile telemedicine workspace, implemented over the 
sustenance of a multi-agent architecture. This workspace provides 
universal access to a wide range of services both for patients and 
professionals. 
4.1 The DIABTel distributed architecture 
The complexity and flexibility required to build the mobile workspace is 
achieved with the definition of a middleware multi-agent architecture 
that comprises a full range of non-expensive and widely accepted 
information technologies offering to users a universal, easy-to-use, on-
line and cost-effective access to telemedicine and information services. 
This architecture allows users to access the information whatever access 
terminal or combination of termináis they choose. It facilitates the use of 
heterogeneous software and/or hardware solutions making possible that 
each Health Care Organization configure the number and the kind of 
services they want to offer to their own users. Moreover, it creates a 
continuous record of the users' actions to monitor all the collaboration 
processes involved in shared care to improve the quality of care. 
This integrated platform embeds several technical implementations to 
allow the access to a wider range of services both for patients and for 
professionals: consultation of patients' records; text and voice mailing; 
printing of reports; alarm management; visit management; telecare; 
teleeducation and intelligent therapy advising. 
The architecture yields on three components: the Agents, the multi-
access Organizer and the datábase. The agents collaborate to guarantee a 
homogeneous access of the users to the system services allowing users to 
access the information whatever access terminal or combination of 
termináis they choose. The number of agents is not limited initially and it 
only depends on the kind of termináis that will be used at each site. 
There are two types of agents: 
• Communication Server agents are in charge of Communications 
with the different user termináis. Each communication agent is in 
charge of managing the communication process between the 
System and one specific user terminal. Their main functionality 
is to receive data from users updating it into the datábase and to 
retrieve data from the datábase to be presented at the user's 
terminal. They have the responsibility of performing the security 
policies for user access control, data confidentiality and data 
integrity during data transfers. 
• Application Server agents: in charge of data analysis and data 
processing. 
The Multi-access Organizer is a message-oriented middleware module 
that is in charge of coordinating the interoperability between all the 
agents integrated into the architecture. The communication between the 
Organizer and the agents is done using "event messages" encapsulated 
into TCP/IP messages. The Organizer receives a message from each 
agent whenever an event occurs and activates the next action to be done. 
Additionally the Organizer includes: Event Registry Services that enable 
the establishment of an event registry and event monitoring services and 
Smart Routing Services that ensure the message gets delivered to the 
appropriate recipients in the correct sequence. 
Fig. 1. The mobile multi-access telemedicine workspace 
The number and nature of the events is not fixed and can be defined at 
any system implementation according to their preferences or specific 
care protocols. During the exploitation of the system, the multi-agent 
architecture allows the inclusión of new events without affecting 
previous service performance. Likewise, the actionthe Organizer triggers 
when a certain event is received is fully configurable. 
The benefit of the multi-access multiagent architecture is that it isolates 
the different communication processes from the rest of the system, so if 
some communication server needs to change its communication protocol 
the system is not affected and only this server has to be modified. The 
definition of independent agents allow each site to have its own preferred 
communication servers working and, even more, the addition of new 
communication servers is transparent to the existing ones. 
4.2. Mobile applications in DIABTel system 
Users can interact with the common workspace using several termináis 
such as Web, PDAs and mobile phones. The user applications running on 
these termináis have a set of common functions both for patients and the 
health care professionals that enable the provisión of the diabetes 
management services described above. 
The main access method to reach the information in the multi-access 
system is the web graphical interface, offering the complete functionality 
of the telemedicine/shared care services with minimal human factors 
limitations. Through the DIABTel web access the users, patients and 
doctor, can consult the electronic patient logbook, insert new data, 
consult or créate new treatments, access to cooperative electronic mail, 
download data firom glucometer, see graphical information: clinical as 
much as system use information, etc. 
The 'mobile applications' implements some of these functionalities, 
adapting them to the limitations of the mobile devices and following the 
considerations exposed in 3.2. 
4.2.1. PDA Smart Assistant application 
The Smart Assistant (SA) application configures one of the most 
advanced approaches to mobile telemedicine close-loop systems in 
diabetes management38. It provides patients with several closed-loop 
control strategies (personal and remote) that offer an augmented 
information self-management environment to increase patient 
empowerment. The SA has an independent executable algorithm 
implemented, based on a non-linear MPC with Bayesian learning. The 
algorithm allows real-time control of the insulin pump based on glucose 
data. It needs also the meal intakes and patient's personal data. The 
algorithm can work in a continuous mode, providing calculation for basal 
insulin rates every 15 minutes. 
The PDA application is a portable and mobile solution which provides 
the patients with flexible tools for data visualisation and with local and 
remote communication services. The Smart Assistant is able to manage a 
local datábase, allowing the patient to work isolated firom the 
telemedicine server without the need of a permanent active 
communication link. On demand by the user, the Patient Unit 
synchronizes the local datábase with the server datábase causing the 
automatic updating of all the new information in both directions. 
Fig. 2. The Togbook' and pump communication scenanos for the PDA apphcation and 
iPAQh2210PDA 
The most characteristic ñinctionality developed for the PDA application 
is the "patient electronic logbook" where the patient could perform the 
following tasks: 
• Manage his/her monitoring data. It implies visualization and 
edition of the patient logbook. It is possible to select the period 
or the single time slice for the data to be introduced or 
visualized. The patient can visualize or insert meal data, glucose 
data, insulin data, device events (needle change, catheter change, 
etc.), individual activities (exercise), additional data (medication, 
stress, etc.) 
• Visualization of graphics and statistical data analyses. Three 
types of graphics are available: plot, pie or temporal. 
• Consult his/her active therapy. The last therapy (insulin and diet) 
proposed by the physician is updated in the application after each 
data synchronization. 
• To download data from the insulin pump or the glucometer. The 
communication with the insulin pump is wireless (Bluetooth or 
IrDA) and with the glucometer is with a serial cable. 
The PDA application can be configured by the patients. Some of the 
options of configuration are preferred language, preferred blood glucose 
units (mg/dl or mmol/1) for the visualization scenarios, preferred starting 
hour for the logbook representation. It is also possible to enter additional 
patient information (weight, date of birth, age, birth date, etc.) It also 
allows introducing authentication data of the patient that uses the 
application, such as login and password and modifying the configuration 
settings for each patient. 
The PDA application is developed in Java in order to be portable on 
múltiple platforms. The portability of the application has been 
successfully tested in conventional PCs and in the PDAs iPAQ hp2210 
and TSM500, both with Windows CE operating system. It's necessary to 
install CrEme v3.24 JVM technology for embedded platforms in order to 
run the application. The TSM500 has GPRS mobile connection 
integrated and for the iPAQ the AudioVox RTM 8000 card was used to 
provide the GPRS communication capabilities. 
The Smart Assistant was evaluated in a clinical experiment and 
demonstrated an improvement in the glycemic control in pump treated 
patients with Type 1 diabetes39. 
4.2.2. WebPDA 
The WebPDA is a Web application developed specifically designed 
taking into account the PDA limitations. The DIABTel Web application 
is optimized for a high-resolution display (1024 x 768) in order to 
present as much information as possible. When accessing with a lower 
resolution device scrolling is allowed, but the PDA resolution is much 
lower so too much scrolling is necessary to access to Web application. 
The 'y' dimensión in PC screens is bigger than the 'x' dimensión, but in 
PDAs is opposite. So a Web application could not be seen properly in a 
PDA screen. 
The WebPDA is a Web application developed specifically designed 
taking into account these PDA limitations. It can be considered a lighter 
versión from the Web application. The functionalities of the WebPDA 
application are: 
• Doctors: Patient selection, Creation and visualization of 
treatments, Electronic logbook visualization, Visualization and 
creation of electronic mails, Visualization and creation of news. 
• Patients: Electronic logbook visualization, Visualization of 
treatments, Visualization of news, Visualization and creation of 
electronic mails. 
Fig. 3. The WebPDA application 
4.2.3. DIABTelMobile 
DIABTelMobile is a mobile telephone application. The functionalities 
are: Introduction, storing, sending and visualization of patient monitoring 
data, visualization of treatment, transmition and reception of messages 
and data downloading from glucometer via bluetooh. 
The DIABTelMobile has been developed in Java Microedition, J2ME, 
using the CLDC 1.0 configuration and the MIDP 2.0 specification. 
Theoretically, it can work in any mobile telephone that implements the 
MIDP 2.0 specification and also the Bluetooth JSR82 specification. But 
the practice shows that not all the mobile telephones that are supposed to 
implement the MIDP 2.0 and the JSR82 specifications make it wholly. 
The application was tested in the TSM520 mobile telephone with 
Windows Mobile Operating System. 
r~= 
- • ' • • ; 
I — ™ — 
-
—4 
Fig. 4. The DIABTelMobile application 
6. Conclusions 
Wireless technologies and the further integration of medical devices into 
mobile scenarios are the pillars for new mobile services that opérate in 
the personal área network optimising the patient intervention for data 
retrieval and communication. 
Moving in this direction, mobile telemedicine increases the quality and 
the quantity of the information collected by patients, improving the 
physician-patient communication and enhancing the decision-making 
process to achieve effective therapy adjustments in a collaborative and 
supervised way. 
The implementation of these mobile services requires the definition of 
distributed architectures including strict strategies for security to 
guarantee patient privacy, data confidentiality and integrity and auditing 
of the clinical acts are mandatory. The limitations of mobile devices, 
such as data processing and batteries duration, have to be taken into 
account in order to develop the users' applications. 
The current challenge in mobile diabetes care is to combine several 
control strategies adapted to patient conditions and glycemic control state 
supported on Communications and decisión aid tools. The augmented 
reliability and availability of continuous glucose sensors, insulin pumps, 
mobile computing technologies and telemedicine services is making a 
reality the implementation of a feasible and reliable ambulatory closed-
loop glucose control system as the best current solution to achieve a good 
metabolic control for insulin-dependent diabetes mellitus patients. The 
research efforts on mobile technologies are moving in this direction 
looking for new solutions to better the quality of care and quality of life 
of people with diabetes. 
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